The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting <i>HER2</i> -mutant NSCLC: a bench-to-bedside review

Zongertinib is the first oral TKI approved for <i>HER2</i>-mutant NSCLC and will provide patients with a convenient, tolerable and effective treatment option in an area of significant unmet need. Next steps include its potential transition to a first-line setting, identification of additional indications, and development of novel combination regimens.